DENTSPLY SIRONA (NASDAQ:XRAY) Sets New 52-Week Low on Disappointing Earnings

Posted by George Bondi on Nov 6th, 2026

DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Free Report)’s stock price hit a new 52-week low during trading on Friday following a weaker than expected earnings announcement. The stock traded as low as $8.14 and last traded at $9.0430, with a volume of 901,655 shares. The stock had previously closed at $10.09.

The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.02). The business had revenue of $836.00 million for the quarter, compared to analysts’ expectations of $861.68 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The firm’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.37 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS.

Key Headlines Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

Positive Sentiment: The company’s third-quarter loss narrowed, according to an earnings report. Dentsply Sirona Q3 Loss Narrows
Negative Sentiment: Quarterly adjusted EPS was $0.29, below the roughly $0.30–$0.31 analysts expected and down from $0.37 a year earlier. Revenue of $836 million also missed the $861.68 million consensus and declined 7.5% year over year. DENTSPLY SIRONA quarterly earnings
Negative Sentiment: 2026 guidance came in below analyst expectations: DENTSPLY SIRONA forecast EPS of $1.20–$1.30 versus a $1.47 consensus, and revenue of $3.5 billion versus $3.6 billion expected. The outlook reinforces concerns about soft demand and ongoing business pressures. DENTSPLY SIRONA Q3 and nine-month results

Analyst Upgrades and Downgrades

Several equities analysts have commented on XRAY shares. Piper Sandler cut their price objective on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, October 9th. Barrington Research decreased their target price on DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Monday, October 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research note on Friday, October 30th. Leerink Partners cut their price target on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a report on Wednesday, October 14th. Finally, Barclays upped their price target on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a report on Monday, August 24th. Three analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.58.

Read Our Latest Report on XRAY

Institutional Trading of DENTSPLY SIRONA

A number of hedge funds have recently added to or reduced their stakes in the business. AlphaCore Capital LLC increased its position in DENTSPLY SIRONA by 9.9% during the 3rd quarter. AlphaCore Capital LLC now owns 14,386 shares of the medical instruments supplier’s stock valued at $127,000 after purchasing an additional 1,298 shares during the period. Private Management Group Inc. raised its holdings in shares of DENTSPLY SIRONA by 18.9% in the 3rd quarter. Private Management Group Inc. now owns 2,936,998 shares of the medical instruments supplier’s stock valued at $26,022,000 after purchasing an additional 466,272 shares in the last quarter. Fulcrum Asset Management LLP purchased a new stake in shares of DENTSPLY SIRONA in the 3rd quarter worth approximately $249,000. Brighton Jones LLC lifted its position in shares of DENTSPLY SIRONA by 7.6% in the 3rd quarter. Brighton Jones LLC now owns 37,673 shares of the medical instruments supplier’s stock worth $334,000 after purchasing an additional 2,668 shares during the period. Finally, CenterBook Partners LP lifted its position in shares of DENTSPLY SIRONA by 46.8% in the 3rd quarter. CenterBook Partners LP now owns 49,760 shares of the medical instruments supplier’s stock worth $441,000 after purchasing an additional 15,858 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Trading Down 6.7%

The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. The stock’s 50 day moving average price is $9.63 and its 200-day moving average price is $11.29. The stock has a market capitalization of $1.88 billion, a P/E ratio of -3.42, a P/E/G ratio of 1.37 and a beta of 0.87.

About DENTSPLY SIRONA

(Get Free Report)

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.